Tiziana Life Sciences Plc (Nasdaq: TLSA), a pioneering biotechnology company developing cutting-edge immunomodulation therapies, has recently been highlighted in a FORBES article. The article focuses on its unique intranasal monoclonal antibody, foralumab, which is currently being studied as a potential treatment for multiple sclerosis and other neurodegenerative diseases.
Foralumab is the world’s first fully human, anti-CD3 mAb in clinical development. This innovative approach has the potential to revolutionize the way we treat neurological conditions.
William A. Haseltine, a Forbes contributing author, recently featured foralumab in an article titled “New T Cell Antibody Treatment Improves Outcomes for Covid Patients”. In his article, Haseltine discussed the promising results of this groundbreaking new therapy, which could revolutionize how Covid-19 is treated.
Foralumab is not just an effective treatment for Covid-19, but also a powerful tool for improving the lives of those with multiple sclerosis. Its unique ability to induce tissue remodeling, recruit immune cells, and limit effector function offers patients a wide range of therapeutic benefits. Its impressive record of success speaks to its remarkable potential to restore health and protect against future viral threats.
The groundbreaking anti-CD3 monoclonal treatment has the potential to revolutionize the way we treat T cell inflammation, as it effectively modulates the response by regulating gene and protein expressions. If further explored, this novel approach could save the lives of thousands of people, providing a much-needed lifeline to those suffering from severe disease.
Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), is revolutionizing the treatment of inflammatory diseases. By binding to the T cell receptor, foralumab suppresses the effector features of multiple immune cell subsets and dampens inflammation, an effect which has been demonstrated in patients with COVID, multiple sclerosis, and healthy normal subjects. Intranasal foralumab Phase 2 trials are set to begin in Q3 2023 in patients with non-active SPMS, paving the way for a new and exciting avenue of immunomodulation therapy.
About Tiziana Life Sciences
Tiziana Life Sciences is paving the way for a revolutionary new approach to immunotherapy. By developing and harnessing transformational drug delivery technologies, they are offering alternative routes of treatment, such as intranasal, oral and inhalation.
Their lead candidate, intranasal foralumab, is a fully human anti-CD3 mAb with a favorable safety profile and encouraging clinical responses. Tiziana’s technology has been patented, with several applications pending, and is set to open up a broad range of possibilities for their pipeline.